[1]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80-83.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
　Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):80-83.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
点击复制

人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
38
期数:
2014年第2期
页码:
80-83
栏目:
出版日期:
2014-03-25

文章信息/Info

Title:
The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases
作者:
白庆双1;  李宁2;  方佩华2;  吴彩兰1;  葛建萍1;  张伟1
1. 天津医科大学第四中心医院临床学院核医学科, 300140;
2. 天津医科大学总医院核医学科, 300052
Author(s):
Bai Qingshuang1;  Li Ning2;  Fang Peihua2;  Wu Cailan1;  Ge Jianping1;  Zhang Wei1
Department of Nuclear Medicine, the Fourth Central Hospital Clinical College of Tianjin Medical University, Tianjin 300140, China
关键词:
受体; 促甲状腺素释放激素; 酶联免疫吸附测定; 甲状腺疾病
Keywords:
Receptor; thyrotropin-releasing hormone; Enzyme-linked immunosorbent assay; Thyroid diseases
DOI:
10.3760/cma.j.issn.1673-4114.2014.02.003
摘要:
目的 探讨促甲状腺激素受体抗体(TRAb)水平对健康人和不同甲状腺疾病患者的临床意义。方法 分别以重组人促甲状腺激素受体(TSHR)膜外区氨基(N)端蛋白和羧基(C)端蛋白作为抗原建立N法和C法,分别检测89名健康者(正常对照组)和254例各种甲状腺疾病患者的血清TRAb水平,组间血清TRAb水平比较采用方差分析,组间阳性率比较采用χ2检验。结果 应用N法检测发现:89名健康者405 nm处的光吸收值(x±s)为0.511±0.135,阳性切限值(x±2s)为0.789,阳性率为4.5%(4/89);初发Graves病(毒性弥漫性甲状腺肿)患者及Hashimoto甲状腺炎伴甲状腺功能减退症(简称甲减)患者405 nm处的光吸收值(x±s)分别为:0.95±0.30、0.61±0.22,高于健康者(F=2.4851和2.0763,P均<0.05);N法对初发Graves病患者、治疗中的Graves病患者、Graves病治疗恢复期患者、Hashimoto甲状腺炎伴甲减患者检测的阳性率分别为73.2%、55.9%、32.1%、45.0%,与正常对照组阳性率之间的差异均有统计学意义(χ2=68.55、56.45、20.71和25.51,P均<0.05);初发Graves病患者阳性检出率高于Hashimoto甲状腺炎伴甲减患者(χ2=4.63,P<0.05),初发Graves病患者与Graves病治疗恢复期患者阳性率之间的差异有统计学意义(χ2=15.94,P<0.05).应用C法检测发现:89名健康者405 nm处的光吸收值(x±s)为0.507±0.142,阳性切限值(x+2s)为0.791,阳性率为3.4%(3/89);Hashimoto甲状腺炎伴甲减患者及初发Graves病患者405 nm处的光吸收值(x±s)为1.18±0.25、0.78±0.25,明显高于健康者(F=3.8164和2.4539,P<0.05);C法对Hashimoto甲状腺炎伴甲减患者、初发Graves病患者、治疗中的Graves病患者、Graves病治疗恢复期患者检测的阳性率分别为:75.0%、46.3%、23.6%、16.1%,与正常对照组阳性率之间的差异均有统计学意义(χ2=66.34、36.87、15.79和7.3,P均<0.05);Hashimoto甲状腺炎伴甲减患者阳性检出率明显高于其他患者(χ2=4.48、19.70和23.68,P均<0.05)。结论 应用N法和C法检测Graves病和Hashimoto患者血清TRAb水平均有重要意义,可用于临床Graves病和Hashimoto甲状腺炎伴甲减患者的诊断、治疗及疗效的评估。
Abstract:
Objective To investigate the level of the thyrotropin recepter antibody (TRAb)in healthy people and patients with different types of thyroid disease,and discuss its clinical significance.Methods Recombinant human thyroid stimulating hormone receptor (TSHR)-ecd N-terminal fragment was used in N method and C-terminal fragment was used in C method as antigens respectively.The serum level of TRAb was measured in 89 healthy people and 254 patients with different types of thyroid disease respectively.The serum levels of TRAb comparison and positive rates comparison between groups were tested by analysis of variance and chi-square test respectively.Results The result of N method:the 405nm light absorption value (x±s)in healthy people was 0.511 ±0.135 with a cut-off value (x+2s)of 0.789.The positive rate was 4.5% (4/89).The 405 nm light absorption value (x±s)in patients with incipient Graves (diffuse toxic goiter)and Hashimoto thyroiditis with hypothyroidism was 0.95±0.30,0.61±0.22 respectively,which was higher than that in healthy people (F=2.4851 and 2.0763,both P<0.05).The positive rate in incipient Graves disease,Graves disease with treatment,Graves disease patients in convalescence stage and Hashimoto thyroiditis with hypothyroidism was 73.2%,55.9%,32.1%,45.0%,respectively.There were significant differences between the above groups and the normal control group (χ2=68.55,56.45,20.71 and 25.51,all P<0.05).The positive rate was significantly higher in incipient Graves disease patients than Hashimoto thyroiditis with hypothyroidism patients (χ2=4.63,P<0.05).There was significant difference in the positive rate between incipient Graves disease and Graves disease patients in convalescence stage (χ2=15.94,P<0.05).The result of C method:the 405 nm light absorption value (x±s)in healthy people was 0.507±0.142 with a cut-off value (x+2s)of 0.791.The positive rate was 3.4% (3/89).The 405 nm light absorption value (x±s)in Hashimoto thyroiditis with hypothyroidism patients and incipient Graves disease patients was 1.18±0.25,0.78±0.25,respectively,which was significantly higher than that in healthy people (F=3.8164,2.4539,P<0.05).The positive rate in Hashimoto thyroiditis with hypothyroidism,incipient Graves disease,Graves disease with treatment,Graves disease patients in convalescenee stage was 75.0%,46.3%,23.6%,16.1%.respectively.There were significant differences among the above groups and the normal control group (χ2=66.34,36.87,15.79,7.30,all P<0.05).The positive rate was significantly higher in Hashimoto thyroiditis with hypothyroidism than other groups (χ2=4.48,19.70,23.68,all PConclusions The N method and C method had important significance for detecting the serum level of TRAb in Graves disease and Hashimoto thyroiditis with hypothyroidism.It may be used in clinical diagnosis,treatment and curative effect evaluation for Graves disease and Hashimoto thyroiditis with hypothyroidism/html>

参考文献/References:

[1] Schwarz-Lauer L, Chazenbalk GD, Mclachlan SM, et al. Evidence for a simplified view of autoantibody interactions with the thyrotropin receptor[J]. Thyroid, 2002, 12(2):115-120.
[2] Takasu N, Yoshimura Noh J. Hashimoto’s thyroiditis:TGAb, TPOAb, TRAb and recovery from hypothyroidism[J]. Expert Rev Clin Immunol, 2008, 4(2):221-237.
[3] Gonzalez C, Hernando M, Cava F, et al. Biological variability of thyroid autoantibodies(anti-TPO and anti-Tg)in clinically and biochemically stable patients with autoimmune thyroid disease[J]. J Clin Lab Anal, 2002, 16(1):37-39.
[4] 时华凤.甲状腺自身抗体定量检测的在临床的应用价值[J].中国医药指南,2012,10(11):143-144.
[5] Giovanella L, Ceriani L, Gzarancini S. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb)in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO)[J]. Q J Nucl Med, 2001, 45(1):115-119.
[6] 张建媛,缪蔚冰.电化学发光法与放射性受体分析法检测促甲状腺激素受体抗体的对比研究[J].国际放射医学核医学杂志,2012,36(1):20-23.
[7] Cho BY. Clinical applications of TSH receptor antibodies in thyroid diseases[J]. J Korean Med Sci, 2002, 17(3):293-301.
[8] 周静,李宁,方佩华,等.1085例各种甲状腺疾病患者及正常人的血清促甲状腺受体抗体含量分析[J].中华内分泌代谢杂志,2010,26(11):959-962.
[9] 李宁,方佩华,张艳丽,等.重组人TSHR片段蛋白建立人TRAb ELISA及临床应用[J].中华核医学杂志,2009,29(5):348-351.

相似文献/References:

[1]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
　Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[2]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[3]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
　Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[4]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
　Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[5]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
　ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[6]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
　LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[7]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
　YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[8]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
　BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[9]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
　CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
[10]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
　LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]

备注/Memo

备注/Memo:
收稿日期:2013-10-18;改回日期:。
基金项目:天津市科技发展计划项目(05YFGDSF02700)
通讯作者:白庆双(Email:bqsh2006@163.com)
更新日期/Last Update: 1900-01-01